• Enanta advanced zelicapavir into a registrational Phase 2b/3 trial for RSV in high-risk adult outpatients.
• Results have not been presented; Phase 2b topline data are expected in 2027.
• The program aims to show faster symptom resolution, with hospitalization tracked as a key secondary outcome.
• A separate pediatric Phase 2b RSV trial is planned to start in Q3 2026, with topline data expected in 2027.
• Management framed the opportunity as a global market above $2 billion, supported by wider at-home RSV testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260618126844) on June 18, 2026, and is solely responsible for the information contained therein.